We analyzed 57 publications devoted to study of genetic mechanisms formation drug resistance Mycobacterium tuberculosis bedaquiline, delamanid, pretomanid, linezolid, and clofazimine. Identification factors MTB make the basis search for new targets in development anti-tuberculosis drugs methods susceptibility testing.

The objective: to evaluate safety and efficacy of bedaquiline in the treatment patients with multiple drug resistant tuberculosis (MDR-TB). Subjects Methods. Clinical data 523 above 18 years old registered for MDR TB as per regimen 4 were retrospectively analyzed. HIV-negative selected divided into two groups by use chemotherapy regimen. Results. In containing bedaquiline, adverse reactions obs...

Abstract Nontuberculous mycobacteria can cause disseminated infections in immunocompromised patients and are challenging to treat because of antimicrobial resistance adverse effects prolonged multidrug treatment. We report successful treatment with bedaquiline, a novel antimycobacterial drug, as part combination therapy for 2 nontuberculous co-infected HIV.

The objective: to determine the rate of treatment success in MDR and XDR pulmonary tuberculosis patients when treated with chemotherapy regimens containing bedaquiline based on a meta-analysis using mathematical modeling. Subjects Methods. We searched analyzed published studies conducted from 2014 2022 Russian Federation. A total 41 publications were found, which 15 included since they containe...

This review discusses small molecule antibiotics approved for clinical use in the time frame 2010-2022. span saw approval of four synthetic (bedaquiline, pretomanid, delafloxacin, tedizolid), nine natural product derivatives (ceftaroline fosamil, cefiderocol, plazomicin, omadacycline, eravacycline, sarecycline, lefamulin, dalbavancin, oritavancin), and one (fidaxomicin).